IGC Pharma Inc. Common Stock (IGC)
Stock · AMEX · Health Care
$0.2462as of 10/16/2026
Price chart
Active signals
IGC Signal Track Record
How signals performed across all stocks →What IGC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -4.1% | 40% | September 28, 2026 |
| Bollinger Band BreakdownActive now | 21 | 0.0% | 38% | July 29, 2026 |
| Bollinger Band Breakout | 21 | -4.9% | 38% | August 27, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -3.5% | 18% | October 9, 2026 |
| Any 20-session window (baseline) | -2.9% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IGC
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 70
- Website
- igcpharma.com/
Fundamentals
- 1-day range
- $0.25$0.2627
- Market cap
- $23.94M
- P/E (trailing)
- —
- P/E (forward)
- -3.18
- EPS (trailing)
- $-0.08
- Dividend yield
- —
- Beta
- 0.51
- Avg. volume
- 718.9K
How IGC Pharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Jun 27, 2025 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
IGC Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
- ATNMActinium Pharmaceuticals Inc. (Delaware) Common Stock$1.13▲ 6.60%Market cap $24.69MP/E 2.95$0.7351$1.74
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- AYTUAytu BioPharma Inc. Common Stock$2.04▲ 1.49%Market cap $25.01MP/E —$1.8$3.07
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) Common Stock | $24.69M | 2.95 | $1.13 | ▲ 6.60% | $0.7351$1.74 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| AYTU Aytu BioPharma Inc. Common Stock | $25.01M | — | $2.04 | ▲ 1.49% | $1.8$3.07 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana MomentBenzinga · 9/29/2026
- IGC Pharma Announces Completion Of 168-Patient Enrollment In Phase 2 Trial Of IGC-AD1 For Alzheimer's Agitation; Topline Data Expected Q4 2026benzinga · 9/28/2026
- IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026Yahoo · 9/28/2026
Insider Activity
Insider Actions →- Claudia Grimaldi · September 25, 2026 · Gift150.0K
- Ram Mukunda · September 25, 2026 · Gift100.0K
- Claudia Grimaldi · June 30, 2026 · Grant2.05M @ $0.27
- Ram Mukunda · June 30, 2026 · Grant2.23M @ $0.27
Institutional Ownership
March 31, 2026
- Total shares held
- 3.90M
- Total value held
- $1.02M
- Institutional holders
- 33
- Unknown1.04M
- Unknown718.4K
- Unknown703.8K
- Unknown484.0K
- Unknown200.8K
- Unknown122.6K
- Unknown113.4K
- Unknown75.0K
- Unknown65.5K
- Unknown59.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused
IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.